CAPR logo

CAPR
Capricor Therapeutics Inc

30,329
Mkt Cap
$1.69B
Volume
102,978.00
52W High
$40.37
52W Low
$4.30
PE Ratio
-12.60
CAPR Fundamentals
Price
$28.93
Prev Close
$29.14
Open
$29.15
50D MA
$31.60
Beta
1.20
Avg. Volume
946,806.89
EPS (Annual)
-$2.26
P/B
6.03
Rev/Employee
$0.00
$1,041.18
Loading...
Loading...
News
all
press releases
Capricor Therapeutics Q1 2026 Earnings Call Transcript
read more...
News Placeholder
More News
News Placeholder
Capricor Therapeutics Says NS Pharma Delays Could Threaten Access To Duchenne Therapy
Capricor sued Nippon Shinyaku over Deramiocel distribution terms, citing pricing issues and patient access risks.read more...
News Placeholder
Nasdaq, S&P 500 Futures Rise Ahead Of Jobs Report As Iran Ceasefire Holds: Why NVDA, IREN, CRWV, RKLB, UPWK, CAPR Are In Focus
Data from Stocktwits shows that retail traders’ sentiment has remained ‘bullish’ on SPY and QQQ this week.
News Placeholder
CAPR Stock Sinks After-Hours: Capricor Launches Legal Fight Over DMD Therapy Rollout Ahead Of FDA Review
Capricor is seeking court approval to pursue an alternative commercialization path for Deramiocel and wants parts of the agreement terminated.
News Placeholder
Capricor Therapeutics (CAPR) Projected to Post Earnings on Tuesday
Capricor Therapeutics (NASDAQ:CAPR) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 12. (View Earnings Report at...
News Placeholder
Oppenheimer & Co. Inc. Cuts Stock Holdings in Capricor Therapeutics, Inc. $CAPR
Oppenheimer & Co. Inc. trimmed its position in shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) by 40.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 80,813 shares of the biotechnology company's stock after selling 54,600 s...
News Placeholder
Capricor Therapeutics (NASDAQ:CAPR) Shares Up 7.1% - Still a Buy?
Capricor Therapeutics (NASDAQ:CAPR) Trading 7.1% Higher - What's Next...
News Placeholder
CAPR Stock In Focus: Ex-Exec Eyed For FDA Role Says Drug Approvals Are Not ‘Best-In-Class’ Signals
Former Capricor executive Houman David Hemmati said FDA approval should be viewed as a “building permit,” not proof a drug is the best option.
News Placeholder
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.5% - What's Next?
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.5% - Should You Sell...
News Placeholder
Moody Aldrich Partners LLC Takes Position in Capricor Therapeutics, Inc. $CAPR
Moody Aldrich Partners LLC purchased a new stake in Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 208,755 shares of the biotechnology compan...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available